Novocure Announces Appointment of Wilco Groenhuysen as Chief Financial Officer
Novocure Ltd., a commercial stage, private oncology company, announced that Wilco Groenhuysen has been appointed as chief financial officer, a newly created position. Mr. Groenhuysen will assume leadership for global finance functions and join the executive management team that is leading the worldwide launch of Novocure's Tumor Treating Fields (TTF) cancer therapy devices.
Prior to joining Novovcure, Mr. Groenhuysen was executive vice president and chief financial officer of Cephalon Inc., through its acquisition by Teva Pharmaceutical Industries Ltd. in 2011. At Cephalon, Mr. Groenhuysen was responsible for worldwide finance, commercial operations, investor relations and risk management. Mr. Groenhuysen led financings in total of over $1.0 billion from equity, convertible debt and credit facilities for Cephalon.
Prior to joining Cephalon in 2007, Mr. Groenhuysen spent 20 years with Philips Electronics in various assignments in Europe, Asia and the United States. At the time he left Philips, Mr. Groenhuysen was the CFO and senior vice president of Philips Electronics North America Corporation.
Other news from the department people
